Premium
TH‐C‐220‐08: Simulating the Effects of Molecular Targeted Drugs on Tumor and Vasculature Development Using An Imaging‐Based, Computational Model
Author(s) -
Adhikarla V,
Titz B,
Jeraj R
Publication year - 2011
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.3613551
Subject(s) - sunitinib , tumor hypoxia , hypoxia (environmental) , medicine , discontinuation , regimen , cancer research , cancer , pharmacology , oncology , chemistry , radiation therapy , oxygen , organic chemistry
Purpose: Molecular targeted therapies affecting tumor and vasculature are currently used as anti‐cancer strategies. However, their effect on the tumor‐ vasculature system is currently poorly understood and quantified. We developed an imaging‐based computational model to simulate tumor and vasculature development, and investigated the effects of Sunitinib, an anti‐ angiogenic receptor tyrosine kinase inhibitor, in silico. Methods: PET scans of tumor hypoxia ([61Cu]Cu‐ATSM) and proliferation ([18F]FLT) were taken as model input. The hypoxia scan reflecting tumor oxygenation (pO2) was used to simulate initial tumor vasculature. Vessel growth rate and tumor cell division probability were hypoxia dependent. The proliferation scan determined the tumor cell division rate. Vascular regression was Sunitinib dependent and tumor cell death hypoxia dependent. Tumor volume and oxygenation were temporally evaluated for drug dosage of 0, 10 and 40 mg/kg/day and therapy discontinuation. Results: Dose dependent changes in tumor pO2 and volume could be observed by day 2 and 5 respectively, indicating a 3 day lag between micro‐environmental and physical characteristic changes. As compared to an untreated tumor, 40 mg/kg/day dosage was twice as effective in decreasing tumor pO2 as compared to 10 mg/kg/day dosage. Discontinuation of therapy on day 5 lead to increase in the tumor pO2, with both regimen pO2 tending to the pO2 of an untreated tumor. The rebound rate of pO2 for the 40 mg/kg/day regimen was four times that of the 10 mg/kg/day dosage. Conclusions: Discontinuation of more aggressive therapy leads to a faster rebound of tumor pO2 due to increased vessel recruitment rate which eventually increases in tumor volume. The model being a part of a more comprehensive tumor‐vascular model will be useful for providing insight into the effects of therapy on the tumor‐vasculature system. Incorporation of patient specific parameters enables the model to be used as a potential tool for tailoring therapy in future.